MUMBAI:
Cipla and
Roche India jointly announced that they have entered into an agreement under which Cipla will promote and distribute key
medicines - tocilizumab (Actemra) and Syndyma, the second brand of Roche's cancer therapy, bevacizumab (Avastin) in India. This partnership is in line with Cipla and Roche's efforts to improve healthcare and increase access to innovative medicines in India, particularly to patients who currently do not have access to them, says a company statement.
Umang Vohra, MD & Global CEO Cipla said: "The prevalence of cancer and rheumatoid arthritis is widely spread across India, and Cipla can contribute to provide broader access to innovative medicines like tocilizumab and bevacizumab."
Lara Bezerra, MD Roche Pharma India said: "This partnership will significantly advance our efforts to expand the reach of, and improve access to, our innovative medicines. This will also enable us at Roche to focus on bringing new, transformative medicines to patients in India".
All Comments ()+^ Back to Top
Refrain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community. Help us delete comments that do not follow these guidelines by marking them offensive. Let's work together to keep the conversation civil.
HIDE